Trinity Biotech
TRIB
93 hedge funds and large institutions have $318M invested in Trinity Biotech in 2014 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 37 increasing their positions, 20 reducing their positions, and 3 closing their positions.
433% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 3
85% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 20
16% more funds holding
Funds holding: 80 → 93 (+13)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
2% less capital invested
Capital invested by funds: $325M → $318M (-$7.13M)
89% less call options, than puts
Call options by funds: $345K | Put options by funds: $3.04M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CIP
Chartwell Investment Partners
Berywn,
Pennsylvania
|
+$6.45M |
| 2 |
Schroder Investment Management Group
London,
United Kingdom
|
+$5.5M |
| 3 |
CCMLC
Cardinal Capital Management LLC (Connecticut)
Greenwich,
Connecticut
|
+$5.46M |
| 4 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
+$5.41M |
| 5 |
WA
Whitebox Advisors
Minneapolis,
Minnesota
|
+$5.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$34.9M |
| 2 |
Northern Trust
Chicago,
Illinois
|
-$2.9M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.87M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$1.62M |
| 5 |
KPCM
Kings Point Capital Management
Great Neck,
New York
|
-$1.01M |
TRIB Hedge Fund Activity: Q2 2014 in Review
93 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in Trinity Biotech (TRIB) for Q2 2014, worth a combined $318M — down 2.2% from $325M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new TRIB positions and 3 closed out — a net gain of 13 holders — while 37 added to existing stakes and 20 trimmed.
The largest buyer was Chartwell Investment Partners, adding an estimated $6.45M. The largest seller was Fidelity Investments, cutting an estimated $34.9M.
- 93 institutional investors held Trinity Biotech (TRIB) as of Q2 2014, up from 80 in Q1 2014.
- Funds reported $318M of Trinity Biotech stock for Q2 2014, down 2.2% quarter-over-quarter.
- 16 funds opened new Trinity Biotech positions in Q2 2014 and 3 closed out, a net change of +13 holders.
- The largest Trinity Biotech buyer in Q2 2014 was Chartwell Investment Partners, an estimated $6.45M added.
- The largest Trinity Biotech seller in Q2 2014 was Fidelity Investments, an estimated $34.9M sold.
Based on aggregated 13F filings for Q2 2014.